NCT07228702Enrolling by invitationPhase 1
Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection
Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection: An Open Label Individual Patient Study
Source: ClinicalTrials.gov · Last updated 3 Jun 2026
Brief summary (registry, in English)
This study aims to use mycobacteriophage therapy, using identified in-vitro effective Mycobacteriophage Muddy\_HRMN0052, along with combination conventional antimycobacterial therapy for their NTM pulmonary disease with Mycobacterium abscessus with goal to reduce infection burden and improve pulmonary disease
- Status (registry)
- Enrolling by invitation
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 1 (estimated)
- First submitted
- 9 Sept 2025
- Start date
- 11 Jan 2026
- Primary completion date
- 31 Oct 2027
- Lead sponsor
- Vancouver Coastal Health
- NCT number
- NCT07228702
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 1
- From 11 Jan 2026 to the primary completion date, 31 Oct 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- non-consent to participation
Who the study is looking for
- consent to participation
Criteria the registry did not label
- This is an individual patient expanded access study specific to one individual based on tailor intervention (Mycobacteriophage)
Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Vancouver General Hospital Non-Tuberculous Mycobacterial Disease Clinic Coordinator of this site? Confirm its status | Vancouver | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.